Also, the clinical study of cadonilimab (a domestic PD‐1/CTLA‐4 bispecific antibody) in treating treatment‐naïve advanced NSCLC (CTR20232128) is actively recruiting, which shows a new paradigm in NSCLC immunotherapy that balances efficacy, safety, and accessibility and provides critical insights for global precision immunotherapy. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.